> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Revises AstraZeneca’s Evusheld Dosing
- URL: https://www.fdaweb.com/fda-revises-astrazenecas-evusheld-dosing/
- Published: 2022-02-25T12:00:00.000Z
- Updated: 2026-09-14T17:34:22.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151241

FDA has revised an AstraZeneca emergency use authorization (EUA) for [Evusheld (tixagevimab co-packaged with cilgavimab)](https://www.fda.gov/media/154704/download?ref=fdaweb.com) to change the initial dose for the authorized use as Covid-19 pre-exposure prevention in certain adults and pediatric patients. “Based on the most recent information and data available, Evusheld may be less active against certain Omicron subvariants,” an [agency notice ](https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-evusheld-dosing?ref=fdaweb.com)says. “The dosing regimen was revised because available data indicate that a higher dose of Evusheld may be more likely to prevent infection by the Covid-19 Omicron subvariants BA.1 and BA.1.1 than the originally authorized Evusheld dose.”

Previously, the authorized dosage was 150 mg of tixagevimab and 150 mg of cilgavimab administered as two separate consecutive intramuscular injections. Under the EUA revision, the agency has increased the initial authorized dose to 300 mg of tixagevimab and 300 mg of cilgavimab. “Patients who have already received the previously authorized dose (150 mg of tixagevimab and 150 mg of cilgavimab) should receive an additional dose of 150 mg of tixagevimab and 150 mg of cilgavimab as soon as possible to raise their monoclonal antibody levels to those expected for patients receiving the higher dose,” FDA says.